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Recent clinical trials have provided unequivocal evidence of major cardiovascular benefits
from low density lipoprotein (LDL) lowering with statins. However, the three critical
unresolved questions about aggressive LDL lowering are the shape of the curve relating
cardiac events to LDL, the best surrogate measurement for assessing therapeutic efficacy and
the best target for LDL therapy. The relation between cardiac events and LDL is curvilinear,
both epidemiologically and during therapy. The benefit of lipid lowering diminishes
progressively and becomes difficult to detect at lower LDL levels without a very large sample
size. Assessment of the benefits of lipid lowering is further confounded by differences in the
level of pretreatment LDL and by the non-LDL lowering effects of statins. Both epidemi-
ologic studies and large randomized clinical trials have produced conflicting results concern-
ing the best LDL target. Failure to reduce the event rate in patients with pretreatment LDL
,125 mg (Cholesterol And Recurrent Events [CARE] trial) alerts us to the risk of
extrapolating epidemiologic data to clinical practice, yet subset analysis of some clinical trials
suggests the greatest benefit appears in those patients with the lowest on-treatment LDL
levels (Scandinavian Simvastatin Survival Study [4S]). This controversy should be resolved in
the next few years by several important on-going trials. In the face of seemingly contradictory
data from current clinical trials, we can only speculate that very aggressive LDL lowering to
,80 mg/dl could be accompanied by a modest therapeutic benefit beyond the current
recommendations of the National Cholesterol Education Program. If any benefit is observed,
it will have to be balanced against a small potential for increased adverse events. (J Am Coll
Cardiol 2000;36:1419–25) © 2000 by the American College of Cardiology
Although statins reduce cardiac events by approximately
25% to 35% over five years in a spectrum of patient subsets
(1–5), three new fundamental questions about more aggres-
sive low density lipoprotein (LDL) lowering remain unre-
solved: 1) what is “the shape of the curve” that relates the
reduction in coronary heart disease (CHD) events to the
magnitude of LDL lowering (6); 2) what is the best
surrogate end point for assessing therapeutic efficacy; and 3)
what is the best LDL target for lipid lowering? For each
question, there is a body of sometimes contradictory infor-
mation to be considered. In this article, we critically analyze
each of these new issues.
Cardiac events and LDL lowering: the issue of a thresh-
old value of LDL. At issue is whether the relation is
continuously curvilinear or whether there is a threshold (at
which a relation only exists above a given cholesterol level).
If there is a threshold relation, then LDL lowering below
that level might have no therapeutic benefit. Large epide-
miologic studies, such as Multiple Risk Factor Intervention
Trial (MRFIT) (7,8), show a curvilinear relation between
serum total cholesterol and coronary disease in patients
without known CHD. Because LDL cholesterol was not
measured in these studies, we must estimate the relation
between LDL cholesterol and cardiac events.
These studies, however, have a limitation that has be-
come important with the development of statin therapy.
Few individuals in the United States had baseline choles-
terol levels ,200 mg/dl when the large epidemiologic
studies were conducted. Consequently, we must use other
populations if we wish to assess the epidemiologic relation
between cholesterol and cardiac events at cholesterol levels
,200 mg/dl. Here we find a paradox. Even though choles-
terol levels ,200 mg/dl lie on the relatively flat portion of
the Western population’s curve, the curvilinear relation
between serum cholesterol and CHD clearly persists to the
level of 160 mg/dl in the Chinese (9). Thus, the Chinese
data provide hope that aggressive lipid lowering might
further reduce cardiac events, yet extrapolation from the low
cholesterol Chinese population to a high cholesterol West-
ern population may be not be justified.
The curvilinear relation found in epidemiologic studies,
however, is far less apparent in data on the effect of therapy
on LDL (Table 1). In the Scandinavian Simvastatin Sur-
vival Study (4S) post-hoc subgroup analysis, the benefit of
the reduction in LDL cholesterol persisted but diminished
progressively, creating a curvilinear relation analogous to the
epidemiologic data (10). In contrast, subgroup analyses of
the West Of Scotland COronary Prevention Study
(WOSCOPS) and the Cholesterol And Recurrent Events
(CARE) trials showed no further reduction in CHD risk
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beyond an “inflection point.” The inflection point is roughly
defined as a 24% reduction in LDL in WOSCOPS and a
LDL level of ,125 mg/dl in CARE (11,12). In essence,
some trial data can be taken to suggest an inflection point,
other data suggest a curvilinear relation. As shown in Figure
1, these apparently contradictory results between trials may
be resolved by consideration of the risk of a cardiac event
before treatment (13). The shape of the “curve” can be
interpreted as curvilinear in high risk patients with coronary
artery disease (CAD) (Fig. 1A), but appears to be relatively
flat for patients not at high risk (Fig. 1B).
Taking the data from the epidemiologic data in healthy
patients, the post-hoc subgroup analyses of the statin trials,
data from the placebo arms of randomized trials, as well as
smaller prospective data bases (14,15), we can make two
reasonable inferences. First, we may speculate that the
relation between coronary events and LDL is curvilinear for
both patients with and without CHD. Second, although a
true inflection point is probably impossible to identify, the
slope of this relation is substantially steeper in the region
above a LDL level of 100 mg/dl than in the region of a
LDL level ,100 mg/dl.
Identification of the best surrogate measurement for
therapeutic efficacy. For assessment of drug efficacy, a
surrogate lipid measurement that can predict long-term
outcomes would have substantial clinical value. Potential
surrogate measures independent of lipids include systemic
markers of inflammation (16), endothelial dysfunction
(17,18) and vessel wall imaging (19). Use of LDL as a
surrogate allows comparison of different LDL lowering
strategies and serves as a guideline for initiation and
maintenance of therapy. Three LDL measurements have
been related to therapeutic efficacy. At issue is which one
best predicts a reduction in the cardiac event rate. The three
leading candidates are baseline LDL, percent LDL reduc-
tion and on-treatment LDL.
BASELINE LDL. Angiographic trials, unlike clinical trials,
use an objective, continuous end point, allowing study of a
much smaller sample size. Nonetheless, a major disadvan-
Abbreviations and Acronyms
CAD 5 coronary artery disease
CARE 5 Cholesterol And Recurrent Events trial
CHD 5 coronary heart disease
LDL 5 low density lipoprotein
MRFIT 5 Multiple Risk Factor Intervention Trial
NCEP 5 National Cholesterol Education Program
Post CABG 5 Post Coronary Artery Bypass Graft
clinical trial
4S 5 Scandinavian Simvastatin Survival Study
WOSCOPS 5 West Of Scotland COronary Prevention
Study
Figure 1. The relation between risk of CHD events and LDL levels
achieved with statin therapy in secondary and primary prevention trials. In
the secondary prevention trials (A), patients are at higher antecedent risk of
a coronary event, and there appears to be a curvilinear relation, similar to
the epidemiologic relation. In the primary prevention trials (B), with lower
risk patients, the relation is much less steep. 4S 5 Scandinavian Simva-
statin Survival Study; CARE 5 Cholesterol And Recurrent Events trial;
LIPID 5 Long-term Intervention with Pravastatin in Ischemic Disease
Study; WOSCOPS 5 West Of Scotland COronary Prevention Study;
AFCAPS/TexCAPS 5 Air Force Coronary/Texas Atherosclerosis Pre-
vention Study. P 5 placebo; T 5 treatment.
Table 1. Major Clinical Trials of Statin Therapy
Trial
LDL Coronary Events*
Years Before After %Change Placebo (%) Rx (%) %RR
4S (n 5 4,444) 5.4 188 120 235 28.0 19.4 234
CARE (n 5 4,159) 5.0 139 98 228 12.9 9.9 224
LIPID (n 5 9,014) 6.1 150 112 225 15.9 12.3 224
WOSCOPS (6,595) 4.9 192 140 226 7.5 5.3 231
AFCAPS/TexCAPS (n 5 6,605) 5.2 150 115 226 6.5 4.9 225
*Coronary events 5 death due to myocardial infarction or coronary heart disease.
4S 5 Scandinavian Simvastatin Survival Study; AFCAPS/TexCAPS 5 Air Force Coronary/Texas Atherosclerosis Prevention Study; CARE 5 Cholesterol And Recurrent
Events trial; LDL 5 low density lipoprotein; LIPID 5 Long-term Intervention with Pravastatin in Ischemic Disease study; RR 5 risk reduction; Rx 5 treatment;
WOSCOPS 5 West Of Scotland COronary Prevention Study.
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tage is that the end point focuses on stenoses, whereas
adverse outcomes are due to plaque instability. Stenoses are
not necessarily unstable, and unstable lesions are not nec-
essarily stenotic (20). Meta-analyses of angiographic trials
have produced conflicting conclusions. Two meta-analyses
of angiographic trials (21,22) concluded that the pretreat-
ment LDL level best predicts angiographic outcome, and
that both percent LDL reduction and on-treatment LDL
are of little predictive value. In contrast, Thompson et al.
(23) found that percent reduction in LDL correlated best
with angiographic outcome, whereas on-treatment LDL
was of little value. Finally, two other meta-analyses (24,25)
found that on-treatment LDL cholesterol was as strongly
correlated with angiographic improvement as percent re-
duction in LDL. In summary, for each of the three potential
surrogate measurements, there is both an individual angio-
graphic trial and an angiographic meta-analysis to suggest
that one of the three is the most predictive, and another to
suggest that it is of little value.
Statin trials that used a clinical end point provide some-
what more insight (Table 1). Among the three potential
surrogate measurements, the best correlation with cardiac
event reduction has been with pretreatment LDL (Fig. 2A).
Pretreatment LDL level predicts a reduction in events
during treatment in the trials with pretreatment LDL
.160 mg/dl. The correlation is less good in trials that began
with lower pretreatment LDL levels. In the CARE trial, for
instance, patients with pretreatment LDL of 150 to
174 mg/dl had reduced coronary events by 35%, and in
those with pretreatment LDL of 127 to 149 mg/dl, events
fell by 26%. But in patients with pretreatment LDL levels
,126 mg/dl, there was no reduction in cardiac events (12).
Similar data have been reported from the Long-term
Intervention with Pravastatin in Ischemic Disease (LIPID)
trial, in which the treatment benefits in those with a baseline
LDL ,135 mg/dl was approximately one-half of those with
LDL .135 mg/dl (3). Taken together, the statin trial data
allow us to conclude that the pretreatment LDL level is an
excellent predictor of therapeutic efficacy (i.e., the higher
the pretreatment LDL level, the greater the benefit of
therapy).
PERCENT LDL LOWERING. The value of percent LDL low-
ering for predicting CHD reduction is best seen in the
post-hoc analysis of the 4S trial. The percent LDL reduc-
tion correlated well with the difference in risk for a cardiac
event. The risk of an event was 18% in the group with
,34% reduction in LDL, which fell to 11% in those with
44% to 70% reduction in LDL (10). On the basis of these
and other similar results, some meta-analyses have con-
cluded that percent LDL lowering may be a more logical
surrogate for therapeutic efficacy than a specific LDL target
(23). Accepting the meta-analyses as valid, however, percent
LDL lowering has a major intrinsic limitation, if the
relation between LDL and cardiac events is indeed curvi-
linear. When the baseline LDL is higher, then any given
level of percent LDL lowering must result in a greater
reduction of cardiac events. Thus, the benefit a patient
derives from treatment is a function of not only the percent
LDL lowering, but also its level before treatment. The
relevance of the interaction between pretreatment LDL and
percent LDL lowering is that the most widely quoted
Figure 2. Relation of percent reduction in CHD events and pretreatment
LDL cholesterol, percent LDL reduction and post-treatment LDL in
major clinical trials of statin therapy. The best correlation is with pretreat-
ment LDL. The regression curve is derived from the following regression
equations: pretreatment LDL (y 5 21.73 1 0.18 pretreatment LDL,
R2 5 0.86, p 5 0.015); percent LDL reduction (y 5 4.69 1 0.82 percent
LDL reduction, R2 5 0.36, p 5 0.17); post-treatment LDL (y 5 3.77 1
0.20 post-treatment LDL, R2 5 0.27, p 5 0.21). See Figure 1 legend for
study acronyms.
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randomized clinical trials began with substantial differences
in baseline LDL (Table 1). This difference probably ex-
plains the somewhat weaker correlation between percent
LDL reduction and cardiac events across studies (Fig. 2B)
than is found for pretreatment LDL. Thus, a reasonable
conclusion is that even though percent LDL lowering is a
useful measure of drug potency and predicts therapeutic
outcome, its use as a surrogate for therapeutic efficacy is
potentially misleading when one wishes to compare studies
or to use it as a criterion for individual patient therapy.
ON-TREATMENT LDL. The argument in favor of on-
treatment LDL derives from the results of angiographic and
vasomotor reactivity trials and from the post-hoc analysis of
the 4S trial. In vasomotor reactivity trials, the correlation
between improvement in endothelial function and on-
treatment LDL levels is modest but statistically significant
(17,18). In the tertiles of on-treatment LDL established by
cut-points of 126 and 105 mg/dl in the 4S trial, major
coronary event rates at four-year follow-up were 18.9%,
13.3% and 11.0%. The lowest LDL tertile is similar to that
recommended by the National Cholesterol Education Pro-
gram (NCEP) for patients with established CHD. None-
theless, on-treatment LDL does not correlate better with
cardiac events than the other two surrogate measurements
(Fig. 2C).
Failure of on-treatment LDL to more clearly predict the
cardiac event rate highlights three limitations in extrapolat-
ing therapeutic implications from the epidemiologic relation
of LDL to cardiac events. First, other risk factors for CHD
(e.g., cigarette smoking, hypertension, diet) shift the curve
upward and to the left (26). This is best illustrated by the
striking differences in cardiac event rates at the same levels
of serum total cholesterol that are found in different West-
ern countries, despite the persistence of the curvilinear
relation in individual populations (27). For instance, Figure
3 shows a fourfold difference in CAD risk between Australia
and France, although the average level of cholesterol in the
two populations is similar. Second, populations with differ-
ent genetics also exhibit major differences in the relation of
LDL to cardiac events. Unlike Western populations, in the
Chinese, a steep slope persists into the range of total
cholesterol 160 mg/dl and LDL cholesterol 60 mg/dl (9),
but in the Japanese, the relation is flat across a wide range of
cholesterol levels (26). Third, statins and other LDL low-
ering therapies alter other lipid fractions that modify CAD
risk, independent of the LDL effect. Statins decrease
triglycerides by 11% to 17% and increase high density
lipoprotein cholesterol by 5% to 7% in clinical trials. A
significant reduction of chylomicrons, very low density
lipoprotein remnants and IDL cholesterol has also been
reported (28). Finally, a direct nonlipid effect of statins may
also preclude epidemiologic data from being used to predict
results of LDL lowering therapy with statins (29). This was
first suggested by WOSCOPS, in which the Framingham
risk prediction model accurately predicted risk in the pla-
cebo arm but underestimated risk reduction in the treatment
arm by 35% (4,30) (Fig. 4). The large number of potential
lipid-independent statin actions include antiplatelet (31,32),
fibrinolytic (32), anti-inflammatory (16), antiproliferative
(29), antioxidant (33) and immunosuppressive effects (34),
inhibition of cholesterol esterification and upregulation of
nitric oxide (35,36). It is possible, given the pharmacologic
differences amongst statins (37), that the magnitude of these
nonlipid-lowering effects may differ between statins.
In summary, all three surrogate LDL measurements have
both value and limitations for predicting therapeutic effi-
cacy. Consequently, all three statin effects need to be
analyzed and reported. Baseline LDL is an excellent pre-
dictor of risk reduction. Percent LDL lowering is also
excellent, but interacts with baseline LDL, confounding
cross-trial comparisons. From a practical standpoint, how-
ever, the clear relation of LDL to clinical events and the
widespread use of LDL targets suggest that on-treatment
LDL has the greatest relevance to the clinical practice of
preventive cardiology.
Figure 3. Interpopulation differences in CAD mortality according to
quartiles of total serum cholesterol levels (27). Between countries, there are
major differences in the cardiac event rate at approximately the same level
of serum cholesterol.
Figure 4. Predicted CHD deaths at different cholesterol levels as predicted
from epidemiologic studies (Framingham risk model) versus observed
therapy (WOSCOPS [30]). One explanation for the difference in cardiac
events is that statins may also reduce cardiac events by non-LDL–lowering
effects. There are a number of variables, however, that may confound such
a comparison. For example, there are differences in age, gender, distribu-
tion of ethnic groups and prevalence of risk factors in the two populations.
As seen in Figure 3, the impact of these and other variables may be
substantial.
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What is the best LDL target? There are two components
to this issue: first, is the NCEP LDL target level of
100 mg/dl for secondary prevention still a reasonable target,
given randomized trial results, and second, will therapeutic
efficacy be increased by much more aggressive LDL lower-
ing?
The first issue concerns the value of lowering LDL below
125 mg/dl. There are two schools of thought. One holds
that a reduction in LDL below the range of 100 to
125 mg/dl provides little additional beneficial effect for
reducing cardiac events (2,12); the alternative position is
that a substantial further reduction in cardiac events can be
obtained with more dramatic LDL lowering (38–40). The
strongest support for the view that the relation between
on-treatment LDL and coronary events has an inflection
point at ;125 mg/dl is provided by the CARE trial. The
CHD events declined progressively as LDL levels fell from
174 to 125 mg/dl; however, from 125 to 71 mg/dl, CHD
events did not decline further (2,12). An important limita-
tion of the CARE analysis is that only 20% of the patients
in the trial had on-treatment levels ,125 mg/dl. Further,
arbitrary post-hoc selection of end points carries the intrin-
sic risk of leading to conclusions that cannot be supported
by prospective studies. Other studies, however, provide
partial support to the idea that LDL lowering below
125 mg/dl has limited value. In WOSCOPS, for instance,
there was no further decrease in cardiac events beyond a
reduction of LDL of 24% (3,11).
The randomized trial that most directly challenges the
conclusions of CARE is the Post Coronary Artery Bypass
Graft (Post CABG) clinical trial, which used an angio-
graphic end point. The trial demonstrated a significant
angiographic and revascularization benefit and 18% lower
clinical events with aggressive LDL lowering to slightly
below the NCEP target level of ,100 mg/dl (38). Because
the on-treatment level of LDL in the moderate treatment
group was only slightly higher than the cut-point chosen for
CARE (135 vs. 125 mg/dl), the data suggest that there may
be substantial benefit from aggressive LDL lowering toward
the NCEP target level of 100 mg/dl. In contrast, a purist
might legitimately question whether vein graft disease, a
model of accelerated atherosclerosis, is directly relevant to
targets for CAD. Clearly, no definitive conclusion can be
drawn from these competing results. The curvilinear epide-
miologic relation between events and cholesterol and the
Post CABG trial results, however, suggest that benefit is
more likely to be spread over the range of LDL between 95
and 135 mg/dl, and probably does not terminate at an LDL
level of 125 mg/dl.
The second question, whether substantially greater LDL
lowering will increase therapeutic efficacy, is arguably the
central issue in lipid-lowering therapy today. There is little
information to guide our reasoning. In summary, epidemi-
ologic data suggest the potential for further benefit, albeit
with a lesser slope. Randomized clinical trial data, exempli-
fied by the differences between CARE and Post CABG,
provide conflicting insights. Very large reductions in LDL
substantially improve endothelial function, however (41);
and endothelial dysfunction probably plays a role in athero-
genesis (42). Thus, Baller et al. (43) found that after six
months of cholesterol lowering with simvastatin, from LDL
level of 165 to 95 mg/dl, coronary flow reserve as measured
by positron emission tomography increased by 20%, with
concomitant regression of angina in most patients. Shechter
et al. (44) found that flow-mediated endothelial relaxation
was significantly better in a group of 28 patients with stable
angina when the mean LDL level was 77 mg/dl than in a
similar group with a mean LDL level of 106 mg/dl. Few
trials have examined the effects of LDL lowering to levels
below the NCEP target. The Harvard Atherosclerosis
Reversibility Project (HARP), the smallest of the angio-
graphic trials, reported no benefit of lowering LDL from
140 to 86 mg/dl (38% reduction) with pravastatin (45). A
larger and more recent angiographic trial—Lipoprotein and
Coronary Atherosclerosis Study (LCAS)—however, re-
ported slowed progression associated with a 24% reduction
in LDL (from 146 to 111 mg/dl) with fluvastatin (46). The
Atorvastatin Versus Revascularization Treatment
(AVERT) trial of 341 stable patients with mild to moderate
CAD suggests that aggressive LDL lowering to 77 mg/dl
with atorvastatin is at least as safe and effective as a strategy
of angioplasty plus a modest reduction in LDL to 119 mg/dl
(47). The sample size and duration of follow-up in all of
these trials was too small to allow detection of any signifi-
cant difference in the hard end points of death or myocardial
infarction. Taken together, the vascular reactivity studies
and limited trial data support the speculation that even more
aggressive lipid lowering will result in a further increment of
reduction in cardiac events. If so, the reduction in events
between LDL target levels of 100 and 70 mg/dl is likely to
be less dramatic than that in higher LDL ranges.
It is also possible that aggressive LDL lowering could
increase the risk of hemorrhagic stroke or malignancy.
There is an established relation between malignancy and
very low cholesterol levels, but the low cholesterol levels are
widely thought to be secondary rather than causal. In the
MRFIT screening study, six-year follow-up data revealed
risk of hemorrhagic stroke to be threefold higher in men
whose total cholesterol was ,160 mg/dl (48). Similarly, the
Honolulu Heart Program, an 18-year follow-up study of
7,850 Japanese men, revealed that the highest incidence of
hemorrhagic stroke occurred in those with total cholesterol
,160 mg/dl (49). Clearly, these epidemiologic results that
relate hemorrhagic stroke risk to nontreatment cholesterol
levels may reflect the presence of concomitant disease and
have no relation to statin therapy. Neither randomized
clinical trial data nor widespread clinical experience has
suggested an increased risk at lower LDL levels, although
the published data are thus far insufficient to allow any
definite conclusion. Consequently, the possibility of finding
an adverse effect of more aggressive cholesterol lowering
cannot be completely ruled out. We may conclude that both
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the benefit and the risk of aggressive LDL lowering to
,80 mg/dl can only be known through randomized clinical
trials with long-term follow-up.
This issue is now being tested in randomized trials. The
Treat to New Targets (TNT) trial compares 10 and 80 mg
of atorvastatin with the predicted outcome LDL levels of 70
and 90 mg/dl, respectively. Patient recruitment was com-
pleted in July 1999. The Study of Effectiveness of Addi-
tional Reductions in Cholesterol and Homocysteine
(SEARCH trial) in the United Kingdom compares 20 to
80 mg of simvastatin. A fascinating aspect of the debate
regarding the best LDL target is illustrated by two trials
sponsored by competing pharmaceutical companies. Both
trials compare 40 mg of pravastatin with 80 mg of atorva-
statin. Depending on the mean entry level of LDL, we
might estimate that the pravastatin dose will reduce LDL to
;100 to 115 mg/dl, whereas the atorvastatin dose will
reduce LDL to ;70 to 80 mg/dl. The Pravastatin or
Atorvastatin Evaluation and Infection Therapy (PROVE
IT) trial, sponsored by the makers of pravastatin, aims to
demonstrate that there is no difference in clinical outcomes
beyond an LDL level close to the current NCEP guideline.
The REVERSAL trial, sponsored by the makers of atorva-
statin, aims to demonstrate plaque regression and stabiliza-
tion by intravascular ultrasound with aggressive lipid low-
ering. The results of these trials should finally resolve what
may reasonably be described as the most important issue in
preventive cardiology today.
Conclusions. There are three critical unresolved questions
relating to statin therapy. Each is a part of the broader issue
of how best to manage elevated LDL cholesterol in patients
at risk for a coronary event. These questions are about the
shape of the curve relating cardiac events to LDL, the best
surrogate measurement for assessing therapeutic efficacy and
the best target for LDL therapy. The current information
allows us to offer a number of speculations. The relation
between cardiac events and LDL is curvilinear, both epide-
miologically and during therapy. The relation is confounded
by large quantitative differences between populations and by
coexisting risk factors. The benefit of lipid lowering is
heavily influenced by the level of pretreatment LDL and by
the non-LDL–lowering effects of statins. The benefit of
lipid lowering is greatest at high levels of pretreatment LDL
and least at low levels. The benefit of lipid lowering
diminishes progressively and becomes difficult to detect at
lower LDL levels.
In the absence of data to guide us, however, we can only
speculate about the best LDL target. Epidemiologic data
suggest that there may be some benefit to greater LDL
lowering. Failure to reduce the event rate in patients with
pretreatment LDL ,125 mg (CARE study) alerts us to the
risk of extrapolating epidemiology to clinical practice, yet
subset analysis of some clinical trials suggests the greatest
benefit appears in those patients with the lowest on-
treatment LDL levels. In the face of this seemingly contra-
dictory data, we can only speculate that given a sufficient
sample size, very aggressive LDL lowering to ,80 mg/dl
could be accompanied by a modest therapeutic benefit
beyond the current NCEP recommendations. In contrast, if
benefit is observed, it will have to be balanced against the as
yet unknown risk of an increase in adverse events.
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